Turn Therapeutics Inc (TTRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$8.94-8.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TTRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of —
TTRX — earnings miss
Dated 2026-08-12
of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Starting the study would add a second disease test for GX-03. A delay would push back evidence for this planned new use.
Supportive ifThe company reports that the first patient received GX-03 in the HS study by June 30, 2027.
Worry ifNo patient has received GX-03 by June 30, 2027, or the company reports that the study was paused or delayed.
Why it matters: The full trial result will test whether the early treatment gap holds in a larger group. It is the key test of GX-03 in atopic dermatitis.
Watch forThe Q1 2027 topline report meets the Week 4 skin-clearance goal. GX-03 shows a clear benefit over vehicle.
Also watch forThe Week 4 skin-clearance goal is missed, or GX-03 does not clearly beat vehicle.
Why it matters: The company had $10.3 million in cash at June's end and expects funds to last into Q3 2027. More cash needs could affect trial plans or add share dilution.
Worry ifA later company update says cash will cover operations into Q3 2027. It reports no added share sale or new debt.
Less concerning ifThe company reports a shorter cash runway, a new share sale, or added borrowing before Q3 2027.
Why it matters: The meeting can clarify the next steps for GX-03. A clear path toward Phase 3 would support the program; new study needs could add time and cost.
Watch forThe company reports that the FDA meeting took place and names a clear next trial step with no new study requested before Phase 3.
Also watch forThe meeting is delayed, or the company reports that the FDA asked for more clinical data before Phase 3.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$357 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $827 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,172 loss on $10,000 · 41.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.